AstraZeneca shares rise on early U.S. approval for leukemia drug

AstraZeneca shares rose 2.7% on Friday after the British drugmaker won earlier-than-expected U.S. regulatory approval for a leukemia drug, in a challenge to rival AbbVie . AstraZeneca said late on Thursday that the U.S. Food and Drug Administration (FDA) had given its go ahead for the company’s Calquence drug to treat chronic lymphocytic leukemia (CLL), one of the most common types of leukemia in adults. …read more

Source:: Yahoo Finance

      

Did you enjoy this article? Join our FREE Newsletter!
I agree to have my personal information transfered to MailChimp ( more information )
Join over 100,000 investors and business leaders worldwide. Get the latest actionable business and investing intelligence before the rest of the crowd.
We hate spam. Your email address will not be sold or shared with anyone else.